Related Experiment Video
Updated: Jul 11, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Digital Tool-Assisted Hospitalization Detection in the Tailored Antiplatelet Initiation to Lessen Outcomes due to
Robert Avram1,2, Julia Byrne3, Derek So4
1University of California San Francisco, San Francisco, CA, United States.
Insights
Monthly mobile surveys effectively detected most cardiovascular hospitalizations in a clinical trial. Geofencing offered earlier detection but had limitations, suggesting digital tools can aid trial efficiency.
Area of Science:
- Clinical Trials
- Digital Health
- Cardiovascular Research
Background:
- Accurate and timely ascertainment of clinical endpoints, such as hospitalizations, is critical for clinical trial success.
- The Tailored Antiplatelet Initiation to Lessen Outcomes Due to Decreased Clopidogrel Response after Percutaneous Coronary Intervention (TAILOR-PCI) Digital Study aimed to improve hospitalization detection using digital tools.
- This pilot study evaluated smartphone-based geofencing and monthly surveys against traditional methods for cardiovascular hospitalization ascertainment.
Purpose of the Study:
- To assess the performance of geofencing-triggered notifications and monthly mobile phone surveys in detecting cardiovascular hospitalizations.
- To compare the effectiveness of these digital tools against conventional site-coordinator ascertainment methods (telephone visits and health record reviews).
Main Methods:
- Participants in the TAILOR-PCI Digital Follow-Up Study used a smartphone app (Eureka Research Platform) for data collection.
- Geofencing was employed to trigger surveys when participants were near a hospital for an extended period (≥4 hours).
- Participants also received monthly surveys to report cardiovascular hospitalizations, with data compared to site coordinator findings.
Main Results:
- Routine monthly surveys detected 88.9% of cardiovascular hospitalizations, while geofencing identified 33.3% (3 out of 9).
- Geofencing provided earlier detection (median 2 days) compared to monthly surveys (11 days) and site coordinators (38 days).
- Algorithmic improvements significantly enhanced the accuracy of geofencing alerts over time, reducing false positives.
Conclusions:
- Monthly digital surveys are effective in detecting the majority of cardiovascular hospitalizations in clinical trials.
- Geofencing enables earlier detection but requires algorithmic refinement to overcome limitations like participant opt-out and false notifications.
- Digital tools show potential to reduce the workload for study coordinators in ascertaining cardiovascular hospitalizations.
Background:
Accurate, timely ascertainment of clinical end points, particularly hospitalizations, is crucial for clinical trials. The Tailored Antiplatelet Initiation to Lessen Outcomes Due to Decreased Clopidogrel Response after Percutaneous Coronary Intervention (TAILOR-PCI) Digital Study extended the main TAILOR-PCI trial's follow-up to 2 years, using a smartphone-based research app featuring geofencing-triggered surveys and routine monthly mobile phone surveys to detect cardiovascular (CV) hospitalizations. This pilot study compared these digital tools to conventional site-coordinator ascertainment of CV hospitalizations.
Objective:
The objectives were to evaluate geofencing-triggered notifications and routine monthly mobile phone surveys' performance in detecting CV hospitalizations compared to telephone visits and health record reviews by study coordinators at each site.
Methods:
US and Canadian participants from the TAILOR-PCI Digital Follow-Up Study were invited to download the Eureka Research Platform mobile app, opting in for location tracking using geofencing, triggering a smartphone-based survey if near a hospital for ≥4 hours. Participants were sent monthly notifications for CV hospitalization surveys.
Results:
From 85 participants who consented to the Digital Study, downloaded the mobile app, and had not previously completed their final follow-up visit, 73 (85.8%) initially opted in and consented to geofencing. There were 9 CV hospitalizations ascertained by study coordinators among 5 patients, whereas 8 out of 9 (88.9%) were detected by routine monthly hospitalization surveys. One CV hospitalization went undetected by the survey as it occurred within two weeks of the previous event, and the survey only allowed reporting of a single hospitalization. Among these, 3 were also detected by the geofencing algorithm, but 6 out of 9 (66.7%) were missed by geofencing: 1 occurred in a participant who never consented to geofencing, while 5 hospitalizations occurred among participants who had subsequently turned off geofencing prior to their hospitalization. Geofencing-detected hospitalizations were ascertained within a median of 2 (IQR 1-3) days, monthly surveys within 11 (IQR 6.5-25) days, and site coordinator methods within 38 (IQR 9-105) days. The geofencing algorithm triggered 245 notifications among 39 participants, with 128 (52.2%) from true hospital presence and 117 (47.8%) from nonhospital health care facility visits. Additional geofencing iterative improvements to reduce hospital misidentification were made to the algorithm at months 7 and 12, elevating the rate of true alerts from 35.4% (55 true alerts/155 total alerts before month 7) to 78.7% (59 true alerts/75 total alerts in months 7-12) and ultimately to 93.3% (14 true alerts/5 total alerts in months 13-21), respectively.
Conclusions:
The monthly digital survey detected most CV hospitalizations, while the geofencing survey enabled earlier detection but did not offer incremental value beyond traditional tools. Digital tools could potentially reduce the burden on study coordinators in ascertaining CV hospitalizations. The advantages of timely reporting via geofencing should be weighed against the issue of false notifications, which can be mitigated through algorithmic refinements.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome III: Diagnostic Studies
Pulse rhythm
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...

